Tirzepatide and Cancer Risk in Individuals with and without Diabetes: A Systematic Review and Meta-Analysis.

Kamrul-Hasan ABM, Alam MS, Dutta D, Sasikanth T, Aalpona FTZ, Nagendra L

Endocrinology and metabolism (Seoul, Korea)15 Jan 2025Cited by 19 (Europe PMC)

PMID39814031PMCIDPMC11898313DOI10.3803/enm.2024.2164PepBankPUB-39814031

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanSystematic reviewSafety outcome
In pooled randomized trials, tirzepatide and control groups had no significant difference in the risk of any cancer.
In plain wordsIn pooled trials, tirzepatide users and control groups had similar overall cancer risk.
Peptide
Tirzepatide
Outcome
No significant changeRisk of any cancer
Study
n = 13,761
Comparator
Placebo or active comparator (pooled)
Analysis
Primary
Outcome group
Cancer risk · Cancer
Studied dose
Dose not stated · 26 to 72 weeksAs given in this study (human).
Measurements
risk ratio
0.78 ratio
any cancer
Source sentences
Summary
Over 26 to 72 weeks, the tirzepatide and pooled control groups had identical risks of any cancer (risk ratio, 0.78; 95% confidence interval, 0.53 to 1.16; P=0.22).
2 context sentences(design, population, supporting numbers)
Summary · context
RCTs involving patients receiving tirzepatide in the intervention arm and either a placebo or any active comparator in the control arm were searched through electronic databases.
Summary · context
Thirteen RCTs with 13,761 participants were analyzed.
Report a problemFND-3981403101
02HumanSystematic reviewSafety outcome
In pooled randomized trials, cancer risk with tirzepatide was comparable to controls in patients with and without diabetes.
In plain wordsIn pooled trials, tirzepatide and control groups had similar cancer risk in people with and without diabetes.
Peptide
Tirzepatide
Outcome
No significant changeCancer risk in patients with and without diabetes
Study
n: not reported in source
Comparator
Placebo or active comparator (pooled)
Outcome group
Cancer risk · Cancer
Studied dose
Dose not stated · 26 to 72 weeksAs given in this study (human).
Source sentences
Summary
The two groups had comparable cancer risks in patients with and without diabetes.
2 context sentences(design, population, supporting numbers)
Summary · context
RCTs involving patients receiving tirzepatide in the intervention arm and either a placebo or any active comparator in the control arm were searched through electronic databases.
Summary · context
Thirteen RCTs with 13,761 participants were analyzed.
Report a problemFND-3981403102
03HumanSystematic reviewSafety outcome
In subgroup analyses of randomized trials, cancer risk with tirzepatide was similar to placebo.
In plain wordsIn subgroup analyses of trials, cancer risk with tirzepatide was similar to placebo.
Peptide
Tirzepatide
Outcome
No significant changeCancer risk versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cancer risk · Cancer
Studied dose
Dose not stated · 26 to 72 weeksAs given in this study (human).
Source sentences
Summary
In subgroup analyses, the risks were also similar in the tirzepatide versus placebo, insulin, and glucagon-like peptide-1 receptor agonist groups.
2 context sentences(design, population, supporting numbers)
Summary · context
RCTs involving patients receiving tirzepatide in the intervention arm and either a placebo or any active comparator in the control arm were searched through electronic databases.
Summary · context
Thirteen RCTs with 13,761 participants were analyzed.
Report a problemFND-3981403103
04HumanSystematic reviewSafety outcome
In subgroup analyses of randomized trials, cancer risk with tirzepatide was similar to insulin.
In plain wordsIn subgroup analyses of trials, cancer risk with tirzepatide was similar to insulin.
Peptide
Tirzepatide
Outcome
No significant changeCancer risk versus insulin
Study
n: not reported in source
Comparator
Insulin
Outcome group
Cancer risk · Cancer
Studied dose
Dose not stated · 26 to 72 weeksAs given in this study (human).
Source sentences
Summary
In subgroup analyses, the risks were also similar in the tirzepatide versus placebo, insulin, and glucagon-like peptide-1 receptor agonist groups.
2 context sentences(design, population, supporting numbers)
Summary · context
RCTs involving patients receiving tirzepatide in the intervention arm and either a placebo or any active comparator in the control arm were searched through electronic databases.
Summary · context
Thirteen RCTs with 13,761 participants were analyzed.
Report a problemFND-3981403104
05HumanSystematic reviewSafety outcome
In subgroup analyses of randomized trials, cancer risk with tirzepatide was similar to glucagon-like peptide-1 receptor agonists.
In plain wordsIn subgroup analyses of trials, cancer risk with tirzepatide was similar to other GLP-1 drugs.
Peptide
Tirzepatide
Outcome
No significant changeCancer risk versus GLP-1 receptor agonists
Study
n: not reported in source
Comparator
GLP-1 receptor agonists
Outcome group
Cancer risk · Cancer
Studied dose
Dose not stated · 26 to 72 weeksAs given in this study (human).
Source sentences
Summary
In subgroup analyses, the risks were also similar in the tirzepatide versus placebo, insulin, and glucagon-like peptide-1 receptor agonist groups.
2 context sentences(design, population, supporting numbers)
Summary · context
RCTs involving patients receiving tirzepatide in the intervention arm and either a placebo or any active comparator in the control arm were searched through electronic databases.
Summary · context
Thirteen RCTs with 13,761 participants were analyzed.
Report a problemFND-3981403105
06HumanSystematic reviewSafety outcome
In pooled randomized trials, overall cancer risk was comparable to controls for the different tirzepatide doses.
In plain wordsIn pooled trials, overall cancer risk at the different tirzepatide doses was similar to control groups.
Peptide
Tirzepatide
Outcome
No significant changeOverall cancer risk across tirzepatide doses
Study
n: not reported in source
Comparator
Placebo or active comparator (pooled)
Outcome group
Cancer risk · Cancer
Studied dose
Dose not stated · 26 to 72 weeksAs given in this study (human).
Source sentences
Summary
The overall cancer risk was also comparable for different doses of tirzepatide compared to the control groups
2 context sentences(design, population, supporting numbers)
Summary · context
RCTs involving patients receiving tirzepatide in the intervention arm and either a placebo or any active comparator in the control arm were searched through electronic databases.
Summary · context
Thirteen RCTs with 13,761 participants were analyzed.
Report a problemFND-3981403106
07HumanSystematic reviewSafety outcome
In pooled randomized trials, the 10-mg tirzepatide dose had a lower risk of any cancer than placebo.
In plain wordsIn pooled trials, only the 10-mg tirzepatide dose had a lower cancer risk than placebo; other doses were comparable to controls.
Peptide
Tirzepatide
Outcome
DecreaseCancer risk with 10-mg dose versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cancer risk · Cancer
Studied dose
10 mg · 26 to 72 weeksAs given in this study (human).
Source sentences
Summary
only a 10-mg tirzepatide dose had a lower risk of any cancer than placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
RCTs involving patients receiving tirzepatide in the intervention arm and either a placebo or any active comparator in the control arm were searched through electronic databases.
Summary · context
Thirteen RCTs with 13,761 participants were analyzed.
Report a problemFND-3981403107
08HumanSystematic reviewSafety outcome
In pooled randomized trials, tirzepatide did not increase the risk of any specific cancer type compared with controls.
In plain wordsIn pooled trials, tirzepatide did not raise the risk of any specific cancer type compared with control groups.
Peptide
Tirzepatide
Outcome
No significant changeRisk of specific cancer types
Study
n: not reported in source
Comparator
Control groups (pooled or separately)
Outcome group
Cancer risk · Cancer
Studied dose
Dose not stated · 26 to 72 weeksAs given in this study (human).
Source sentences
Summary
Furthermore, compared to the control groups (pooled or separately), tirzepatide did not increase the risk of any specific cancer types.
2 context sentences(design, population, supporting numbers)
Summary · context
RCTs involving patients receiving tirzepatide in the intervention arm and either a placebo or any active comparator in the control arm were searched through electronic databases.
Summary · context
Thirteen RCTs with 13,761 participants were analyzed.
Report a problemFND-3981403108
09HumanSystematic reviewSafety outcome
In pooled randomized trials, serum calcitonin rose more with 10- and 15-mg tirzepatide doses than with placebo.
In plain wordsIn pooled trials, blood calcitonin rose more with 10-mg and 15-mg tirzepatide doses than with placebo.
Peptide
Tirzepatide
Outcome
IncreaseSerum calcitonin increment
Study
n: not reported in source
Comparator
Placebo
Outcome group
Thyroid function · Endocrine and hormones
Studied dose
10 mg and 15 mg · 26 to 72 weeksAs given in this study (human).
Source sentences
Summary
Despite greater increments in serum calcitonin with 10- and 15-mg tirzepatide doses than with placebo
2 context sentences(design, population, supporting numbers)
Summary · context
RCTs involving patients receiving tirzepatide in the intervention arm and either a placebo or any active comparator in the control arm were searched through electronic databases.
Summary · context
Thirteen RCTs with 13,761 participants were analyzed.
Report a problemFND-3981403109
10HumanSystematic reviewSafety outcome
In the included randomized trials of tirzepatide, no cases of papillary thyroid carcinoma were reported.
In plain wordsIn the included trials of tirzepatide, no cases of papillary thyroid cancer were reported.
Peptide
Tirzepatide
Outcome
No significant changePapillary thyroid carcinoma cases
Study
n: not reported in source
Outcome group
Cancer risk · Cancer
Studied dose
Dose not stated · 26 to 72 weeksAs given in this study (human).
Source sentences
Summary
the included RCTs reported no cases of papillary thyroid carcinoma.
2 context sentences(design, population, supporting numbers)
Summary · context
RCTs involving patients receiving tirzepatide in the intervention arm and either a placebo or any active comparator in the control arm were searched through electronic databases.
Summary · context
Thirteen RCTs with 13,761 participants were analyzed.
Report a problemFND-3981403110

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.